A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory...

[HTML] placera.se

[HTML][HTML] Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis (gMG)(Cision)

T Avanza - placera.se
Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to
include the treatment of refractory generalised myasthenia gravis (gMG) in children and …
相关文章
[HTML] mfn.se

[HTML][HTML] AstraZeneca: Soliris approved in Japan for paediatric patients with generalised myasthenia gravis (gMG)

D Mode - mfn.se
First-in-class C5 inhibitor is the only targeted treatment approved for this patient population
in Japan. Soliris reduced disease severity and symptoms with sustained improvements over …
相关文章
[HTML] mfn.se

[HTML][HTML] AstraZeneca: Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis (gMG)

D Mode - mfn.se
Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to
include the treatment of refractory generalised myasthenia gravis (gMG) in children and …
相关文章
[HTML] mfn.se

[HTML][HTML] AstraZeneca: Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis (gMG)

D Mode - mfn.se
Soliris (eculizumab) has been recommended for marketing authorisation in the European
Union (EU) for expanded use to include the treatment of refractory generalised myasthenia …
相关文章
[HTML] placera.se

[HTML][HTML] Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis (gMG)(Cision)

T Avanza - placera.se
Potential approval for Soliris would mark first and only targeted treatment for this patient
population in the European Union. The first-in-class C5 inhibitor reduced disease severity …
相关文章